Suppr超能文献

常规特布他林对气道对吸入布地奈德反应的影响。

Effect of regular terbutaline on the airway response to inhaled budesonide.

作者信息

Wilding P J, Clark M M, Oborne J, Bennett J A, Tattersfield A E

机构信息

Division of Respiratory Medicine Unit, City Hospital, Nottingham, UK.

出版信息

Thorax. 1996 Oct;51(10):989-92. doi: 10.1136/thx.51.10.989.

Abstract

BACKGROUND

The rebound increase in bronchial reactivity and fall in forced expiratory volume in one second (FEV1) following treatment with beta agonists seen in several studies has occurred regardless of concurrent steroid therapy. Little is known about the effect of adding beta agonists to corticosteroids, but in a recent study regular treatment with terbutaline appeared to reduce some of the beneficial effects of budesonide. The effects of budesonide alone and in combination with regular terbutaline treatment on lung function, symptom scores, and bronchial reactivity were therefore examined.

METHODS

Sixteen subjects with mild stable asthma inhaled budesonide 800 micrograms twice daily for two periods of 14 days with terbutaline 1000 micrograms three times daily or placebo in a double blind crossover fashion. FEV1 and the dose of histamine or adenosine monophosphate (AMP) causing a 20% fall in FEV1 (PD20) were measured before and 12 hours after the final dose of treatment, and changes from baseline were compared. Seven day mean values for daily morning and evening peak expiratory flow (PEF) values, symptom scores, and rescue medication were compared before and during treatment.

RESULTS

Morning and evening PEF rose more with budesonide plus terbutaline than with budesonide alone, with a mean difference of 19 l/min occurring in the evening (95% confidence interval (CI) 2 to 36). There was no difference in symptom scores during treatment. Following treatment the mean increase in FEV1 was 150 ml higher with budesonide alone (95% CI-10 to 300). There was no difference between treatments in change in histamine and AMP PD20.

CONCLUSIONS

Evening PEF was greater when budesonide was combined with regular terbutaline. There was no evidence of a difference in bronchial reactivity following the two treatment regimens. The findings of a previous study were not confirmed as the reduction in FEV1 after budesonide and terbutaline was smaller and not statistically significant. Further work is needed to determine whether this disparity in findings in the two studies is due to a type 2 statistical error in this study or a spurious finding in the previous study.

摘要

背景

多项研究表明,无论是否同时使用类固醇治疗,使用β受体激动剂治疗后均会出现支气管反应性反弹增加以及一秒用力呼气量(FEV1)下降的情况。关于在皮质类固醇基础上加用β受体激动剂的效果知之甚少,但在最近一项研究中,定期使用特布他林似乎会降低布地奈德的一些有益效果。因此,研究了单独使用布地奈德以及布地奈德与定期使用特布他林联合治疗对肺功能、症状评分和支气管反应性的影响。

方法

16名轻度稳定期哮喘患者以双盲交叉方式,在两个为期14天的时间段内,每天两次吸入800微克布地奈德,同时每天三次吸入1000微克特布他林或安慰剂。在最后一剂治疗前和治疗后12小时测量FEV1以及导致FEV1下降20%的组胺或单磷酸腺苷(AMP)剂量(PD20),并比较相对于基线的变化。比较治疗前和治疗期间每日早晚最大呼气流量(PEF)值、症状评分和急救药物的7天平均值。

结果

布地奈德加特布他林组早晚PEF的升高幅度大于单独使用布地奈德组,晚上平均差异为19升/分钟(95%置信区间(CI)2至36)。治疗期间症状评分无差异。治疗后,单独使用布地奈德组FEV1的平均增加量高150毫升(95%CI -10至300)。组胺和AMP PD20的变化在两种治疗之间无差异。

结论

布地奈德与定期使用特布他林联合使用时,晚上的PEF更高。两种治疗方案后的支气管反应性无差异证据。之前一项研究的结果未得到证实,因为布地奈德和特布他林治疗后FEV1的降低幅度较小且无统计学意义。需要进一步研究以确定两项研究结果的差异是由于本研究中的II型统计错误还是之前研究中的虚假发现。

相似文献

本文引用的文献

5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验